Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Deepak Bhatt, MD, MPH, MBA
Credit: Mount Sinai Heart

Endogenous hypercortisolism was identified in more than a quarter of patients with 

, according to findings presented at the 

American College of Cardiology's Annual Scientific Session (ACC.26)

Results from the screening portion of the MOMENTUM trial results suggest the condition may be a substantially more common and underrecognized driver of treatment-resistant hypertension than current clinical practice assumes.

“Resistant hypertension increases the risk of cardiovascular events like heart attacks, strokes, and heart failure, as well as kidney damage,” said Deepak L. Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital and Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. “MOMENTUM shows that hypercortisolism contributes to resistant hypertension in over a quarter of patients and that screening for hypercortisolism in these challenging-to-treat patients may help physicians provide more personalized care.”

MOMENTUM Study Design and Testing Methodology

MOMENTUM (NCT06829537) was a prospective, multicenter observational study conducted at 50 US sites. Eligible participants were adults aged 18 years or older with resistant hypertension defined by American Heart Association criteria: systolic blood pressure of 130 mmHg or greater despite use of 3 or more antihypertensive medication classes including a diuretic at maximally tolerated doses, or use of 4 or more medications from different classes regardless of blood pressure level.

Each participant was evaluated for hypercortisolism using the 1-mg overnight dexamethasone suppression test (DST), with hypercortisolism defined as a post-DST cortisol level greater than 1.8 mcg/dL in the setting of adequate dexamethasone levels of 140 ng/dL or higher.

Key exclusion criteria were designed to minimize false-positive results and included white-coat hypertension, confirmed nonadherence to antihypertensive medications, systemic glucocorticoid exposure, impaired renal function, acute illness, severe untreated sleep apnea, and oral contraceptive use.

The primary endpoint was the prevalence of hypercortisolism. Secondary endpoints included clinical and laboratory characteristics associated with hypercortisolism, markers of primary aldosteronism, prevalence of cortisol-aldosterone co-secretion, and sex-based differences in frequency.

Hypercortisolism Identified in 27% of Screened Patients

Results presented at ACC.26 indicated 297 of the 1086 patients screened, or 27.3%, met the study definition for hypercortisolism. Among the subset of participants with hemoglobin A1c of 7.5% or higher who were taking 3 or more antihypertensive medications, the prevalence rose to 32.6%, the company reported.

According to investigators, the MOMENTUM results, if replicated, may support broader screening with the standardized DST in resistant hypertension workups.

The MOMENTUM findings should be interpreted in the context of several limitations. As an industry-sponsored observational prevalence study, the results reflect provider-referred patients at specialty sites and may not represent the broader resistant hypertension population. The DST, while standardized, can produce false positives, and the study exclusion criteria aimed to minimize but not eliminate this risk.

The results come on the heels of the CATALYST trial, which was a 2-part trial funded by Corcept Therapeutics. In the first half of the CATALYST trial, investigators found hypercortisolism in 23.8% of the 1057 patients screened with difficult-to-control type 2 diabetes. In the second half, treatment with mifepristone significantly reduced HbA1c by 1.32% compared to placebo and improved weight management over 24 weeks.

“It is now clear that hypercortisolism is more common than previously assumed in patients whose hypertension and diabetes don’t respond to standard-of-care treatments,” said Bill Guyer, PharmD, chief development officer at Corcept Therapeutics. “We are grateful to the investigators and patients who have participated in this research and hope that the findings will provide critical information to support increased screening for hypercortisolism, more accurate diagnoses and improved treatment options.”

Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study

. Presented at American College of Cardiology's Annual Scientific Session (ACC.26). March 27-30, 2026. New Orleans, LA.

Corcept Therapeutics. Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session – Corcept Therapeutics, Incorporated. Corcept Therapeutics, Incorporated. Published March 28, 2026. Accessed March 29, 2026. 

https://ir.corcept.com/news-releases/news-release-details/corcept-presents-data-momentum-trial-american-college-cardiology

Articles

Results of the MOMENTUM trial suggest the prevalence of hypercortisolism in resistant hypertension could be greater than previous estimates have indicated.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Type 2 Diabetes

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension

Navin Kapur, MD, is the director of the Acute Circulatory Support Program and associate director of the Cardiac Catheterization Laboratory at Tufts Medical Center.

Gregg Stone, MD, is the director of academic affairs for the Mount Sinai Heart Health System and professor of medicine (cardiology) and of population health sciences and policy at the Icahn School of Medicine at Mount Sinai.

LV Unloading Before Delayed PCI Reduces Infarct Size by 1%, With Gregg Stone, MD, and Navin Kapur, MD

Left ventricular unloading and a 30 minute delay prior to percutaneous coronary intervention (PCI) seems to reduce infarct size by 1% in patients with 

ST-segment elevation myocardial infarction (STEMI)

, according to data from the STEMI-Door to Unload (DTU) study.

American College of Cardiology (ACC) Scientific Sessions 2026

 by Gregg Stone, MD, FACC, director of academic affairs for the Mount Sinai Heart Health System and professor of medicine (cardiology) and of population health sciences and policy at the Icahn School of Medicine at Mount Sinai, and Navin Kapur, MD, director of the Acute Circulatory Support Program and associate director of the Cardiac Catheterization Laboratory at Tufts Medical Center.

“What we found was that there was no significant difference in infarct size between the 2 groups, although the infarct size was about 1% smaller as measured as the percent of total left ventricular mass in the group that got unloaded with the Impella device compared to the control group,” Stone told 

 in an exclusive interview. “I would have expected about a 2 to 3% increase in infarct size, because there was a 47-minute delay in the group that got the Impella. So, the device is doing something to reduce infarct size, but it wasn’t quite significant within this trial.”

STEMI-DTU was an open-label, randomized controlled trial conducted across 55 hospitals worldwide. Patients aged 18 to 85 years were eligible for inclusion if they had no prior myocardial infarction and presented with acute anterior STEMI within 1 to 6 hours of symptom onset before hospital arrival. Patients who had been transferred from an outside hospital at which an invasive coronary procedure had been attempted were excluded, in addition to those with cardiogenic shock, unwitnessed cardiac arrest, drug-eluting stents, and other conditions.

The study’s primary endpoint was ischemic stroke normalized to left ventricular mass (IS/LVM) as evaluated by cardiac magnetic resonance (CMR) at 3-5 days following index. The secondary powered effectiveness endpoint was the hierarchical composite of cardiovascular mortality, cardiogenic shock within ≥24 hours of enrollment, left ventricular assist device or heart transplant, heart failure, implantable cardioverter defibrillator, or cardiac resynchronization therapy, and IS/LVM as evaluated by CMR at 3 to 5 days post-procedure.

A total of 527 patients with anterior STEMI without cardiogenic shock were enrolled in the trial and randomly assigned in a 1:1 ratio to either the treatment – trans-valvular micro-axial flow pump (TV-mAFP) plus delayed PCI (n = 262) – or the control group (n = 265). Time to PCI was longer in the treatment group by a median of 40 minutes (96 [78, 122] vs. 56 [40, 72] minutes; 

 <.0001). Total ischemic time was longer in the treatment group as well, by a median of 47 minutes (212 [174, 272] vs. 165 [134, 220] minutes; 

IS/LVM was 30.8 +/- 16.2% in the treatment arm and 31 +/- 16.9% in control, with a mean difference of -1.1% (95% CI, -4.2% to 2%; 

 = .5). Major bleeding and vascular complications at a 30-day follow-up also occurred more frequently in the treatment arm when compared with a prespecified performance goal, as well as with the control group.

These results were ultimately not statistically significant, leading STEMI-DTU to report that TV-mAFP and delayed PCI did not reduce infarct size compared to PCI alone in this population. However, the roughly 1% reduction, Kapur and Stone believe, reflects a significant opportunity for therapy moving forward – and fertile ground for future studies.

“We’re excited because this opens up a new chapter of investigation,” Kapur told 

. “There’s much more work to do, but you can see a number of different study designs coming out – for the first time, we can say that putting in an LV support device, even if you had to delay up to 30 minutes, is not going to increase the infarct size. That’s where the investigative opportunities open up.”

Editors’ Note: Stone reports disclosures with Bioventrix, Abbott, Mount Sinai Hospital, Occlutech, Alleviant, Boehringer Ingelheim, and others. Kapur reports employment with Abiomed/J&J Medtech Heart Recovery.

Kapur N, Mangner N, Aghili N, et al. Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results from the STEMI-Door to Unload Randomized Clinical Trial. Abstract presented at the American College of Cardiology Annual Scientific Sessions (ACC.26) in New Orleans, LA, March 28-30, 2026.

Kapur, N, Mangner, N, Aghili, N. et al. Left Ventricular Unloading in Anterior STEMI without Shock: The STEMI Door to Unload (DTU) Randomized Controlled Trial. 

https://doi.org/10.1016/j.jacc.2026.03.071

Videos

Although not statistically significant, the reduction represents a potential new pathway for treating patients with STEMI.

Structural Heart Disease

Strategic Alliance Partnership

Tolerability of Roflumilast Cream 0.05% in Infants with Eczema, With Lawrence Eichenfield, MD

Lawrence F. Eichenfield, MD, of Rady Children’s Hospital, spoke in another segment of his 

 interview on recent long-term safety and tolerability data drawn from the INTEGUMENT-OLE study, reflecting on what roflumilast cream .05% (Zoryve) could be for toddlers and preschoolers with 

These findings were poster data presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

. Building on the efficacy findings established in the INTEGUMENT-PED pivotal trial and the phase 2 INTEGUMENT-INFANT data presented at this year's meeting, Eichenfield turned in the second part of his conversation with 

 to address these new data from INTEGUMENT-OLE.

Eichenfield was careful to distinguish between 2 related but separate concepts. Tolerability, as he framed it, is the day-to-day experience of using this topical agent, whether it burns, stings, or leads to application site reactions resulting in cessation.

Safety is the broader question of whether accumulated use over time produces immunosuppression or other systemic impacts. On both of these subjects, Eichenfield said, the INTEGUMENT-OLE open-label extension study provided reassuring answers. More than 97% of participants showed no evidence of local irritation at any assessment point across the 56-week study period.

“They also asked the caretakers about reports of stinging or burning at each visit, and it was less than 1.8% of participants at any time point who, over that 56 week time period, had problems with tolerability,” Eichenfield said.

On the safety side, treatment-emergent adverse events (AEs) taking place at rates of 4% or higher were consistent with what clinicians expect in any cohort of 2- to 5-year-olds followed over a full year. Specifically, there were upper respiratory infections at a rate of 8.7%, some nasopharyngitis, some fever, and a small number of gastrointestinal events.

None of AEs, Eichenfield added, were signals attributable to the drug. Serious adverse events were rare, and those viewed as treatment-related were minimal. When asked how roflumilast cream fits within the overall management landscape for this age cohort, Eichenfield acknowledged concerns over topical corticosteroids among caregivers may be higher than ever, whether or not this view is always warranted.

This creates a practical need for a non-steroidal option for families to use with confidence, Eichenfield added. He also pointed to the INTEGUMENT-INFANT data as the next frontier for this research into roflumilast, describing the evidence base as now extending to children under 2, a group where the unmet need is even more acute and where the availability of a safe, effective non-steroidal option would be especially impactful.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting. Arcutis. March 28, 2026. 

https://www.globenewswire.com/de/news-release/2026/03/28/3264182/0/en/Arcutis-Presents-New-Phase-2-Results-in-Infants-with-Atopic-Dermatitis-in-Late-Breaking-Session-Today-at-the-2026-American-Academy-of-Dermatology-Annual-Meeting.html

Eichenfield L. New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD. HCPLive. March 29, 2026. Accessed March 28, 2026. 

https://www.hcplive.com/view/new-data-support-roflumilast-cream-infants-eczema-over-4-weeks-lawrence-eichenfield-md

In this segment of his interview, Eichenfield highlights the safety and tolerability of roflumilast cream for infants with atopic dermatitis in INTEGUMENT-OLE.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Roflumilast Cream 0.05% Well Tolerated in Children with Eczema, With Lawrence Eichenfield, MD

New Data Support Roflumilast Cream in Infants with Eczema at 3 Months of Age, With Lawrence Eichenfield, MD

New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD

Roflumilast cream .05% (Zoryve) has demonstrated meaningful efficacy and a favorable safety profile among infants with mild to moderate atopic dermatitis as young as 3 months, according to new data.

These phase 2 data were presented during a late-breaking podium session at the 

 in Denver, adding new information to the growing body of evidence behind roflumilast cream for infants aged 3 months to less than 24 months with mild to moderate disease. To discuss these data, 

 spoke at AAD with Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine.

“It had been studied, as you pointed out, in that four week time period, once a day over four weeks,” Eichenfield said. “It was nice that they could do it in a short period of time and show the difference from the vehicle and show efficacy.”

Eichenfield, the presenting author of the INTEGUMENT-INFANT data, opened his discussion by framing the study within the longstanding limitations of topical drugs in this vulnerable patient population. Continuous use of topical corticosteroids is not appropriate for young children, he noted, and even intermittent utilization requires careful management of quantity and frequency.

In this open-label trial, during which 101 infants were evaluated when using roflumilast cream .05% over 4 weeks, there were 96 participants who completed treatment. Eichenfield and colleagues found 34.4% attained validated Investigator Global Assessment (IGA) success and 49% attained a score of clear or almost clear by the fourth week. The team found scalp involvement, present at baseline in 40 of these infants, improved well, with 67.5% showing clearance success at the 4-week mark.

On the Eczema Area and Severity Index (EASI), 58.3% of these participants achieved at least 75% improvement by Week 3, with 34% already attaining this level at Week 2. Eichenfield et al also highlighted the notable caregiver-reported itch outcomes, with more than 72% of infants showing meaningful itch improvement by the 4-week mark, and nearly half showing at least a 25% improvement in their itch level within just 10 minutes of application.

This was a result Eichenfield noted directly in his presentation remarks as evidence of rapid relief for both infants and their families. In terms of safety, roflumilast cream’s profile was described as reassuring and consistent with what was seen in the older INTEGUMENT-PED cohort. There were no serious adverse events observed, as only 1 individual discontinued due to an adverse event. Additionally, at least 97.9% of infants had no application site irritation throughout the analysis.

Arcutis has announced its plans to submit a supplemental New Drug Application (sNDA) for roflumilast cream .05% in infants aged 3 months to less than 24 months in the second quarter of 2026.

Smith T. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic Dermatitis. HCPLive. February 2, 2026. Accessed March 28, 2026. 

https://www.hcplive.com/view/positive-topline-data-released-roflumilast-cream-infants-atopic-dermatitis

This AAD interviews covers new, late-breaking findings on roflumilast cream 0.05% (Zoryve) in infants with mild‑to‑moderate atopic dermatitis.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Risankizumab (Skyrizi; AbbVie) demonstrated significantly greater skin clearance than deucravacitinib (Sotyktu; Bristol Myers Squibb) at week 16 across a broad range of patient subgroups in adults with biologic-naïve moderate plaque psoriasis, according to a subgroup analysis of the phase 4 IMMpactful trial presented at the 

 held in Denver, Colorado, from March 27-31.¹

The results extend the primary efficacy findings of IMMpactful — first reported at the Fall Clinical Dermatology Conference in October 2025 — to subgroup populations defined by age, sex, race, smoking status, BMI, baseline disease severity, and presence of psoriatic arthritis.¹

IMMpactful (NCT06333860) is an Abbvie-funded, ongoing phase 4, multicenter, randomized, open-label, efficacy assessor-blinded study comparing risankizumab with deucravacitinib in adults with moderate plaque psoriasis. Eligible patients had a body surface area involvement of 10–15%, a PASI score ≥12, and a static Physician Global Assessment (sPGA) score of 3, and had not previously received biologic therapy. Patients were randomized 1:2 to subcutaneous risankizumab 150 mg at baseline and week 4 (n = 131) or oral deucravacitinib 6 mg once daily (n = 262) for the initial 16-week period. Co-primary endpoints were PASI 90 and sPGA 0/1 at week 16. The study is ongoing, with 52-week data anticipated at a future congress.¹

Baseline demographics were comparable between arms. Mean age was 47.3 versus 44.8 years, mean PASI was 15.7 versus 15.3, and mean affected BSA was 13.2% versus 13.0% in the risankizumab and deucravacitinib groups, respectively.¹

Investigator Nina Magnolo, MD, Professor of Dermatology and Neurodermatology at the University Hospital Münster, and colleagues found that in the overall population, risankizumab achieved significantly higher rates of PASI 90 (57.3% vs 22.9%), sPGA 0/1 (80.2% vs 39.7%), and PASI 100 (27.5% vs 6.5%) compared with deucravacitinib at week 16, all at 

The subgroup analysis at AAD 2026 examined whether this advantage was consistent across clinically relevant patient characteristics. Across nearly all subgroups examined, risankizumab maintained a statistically significant advantage on both PASI 90 and sPGA 0/1.¹

For PASI 90, differences favoring risankizumab reached statistical significance (

 ≤.05) in patients under 40 years (77.8% vs 18.2%), those aged 40 to <65 years (54.5% vs 21.8%), White patients (58.1% vs 22.8%), non-White patients (50.0% vs 24.3%), male patients (60.0% vs 23.8%), female patients (53.8% vs 23.3%), current smokers (59.5% vs 22.1%), previous or never smokers (56.2% vs 23.2%), all three BMI categories, patients with baseline PASI above the median of 14.4 (52.8% vs 21.6%), patients with baseline PASI at or below the median (69.0% vs 23.3%), and patients without psoriatic arthritis (55.7% vs 23.3%).¹

The one subgroup where statistical significance was not reached was patients aged ≥65 years — though the proportion numerically favored risankizumab (77.8% vs 31.8%); the authors attributed this to the small sample size in that age stratum.¹ Similarly, in the small psoriatic arthritis subgroup (n = 9 risankizumab, n = 22 deucravacitinib), the PASI 90 difference was numerically but not statistically significant (47.1% vs 18.2%).¹

The sPGA 0/1 results followed a parallel pattern, with risankizumab achieving statistically significant superiority (

 ≤.01) across all subgroups except patients aged ≥65 years.¹

Safety through week 16, previously reported at the Fall Clinical Dermatology Conference, was consistent with the established profiles of both agents.¹

IMMpactful is among the first prospective head-to-head randomized trials directly comparing an IL-23 inhibitor with a TYK2 inhibitor in psoriasis, addressing a gap that has previously required indirect methods. A 2024 matching-adjusted indirect comparison (MAIC) published in 

 analyzed data from the UltIMMa-1 and UltIMMa-2 risankizumab trials and the POETYK PSO-1 and PSO-2 deucravacitinib trials, finding significantly higher rates of PASI 75, PASI 90, PASI 100, and DLQI 0/1 with risankizumab at both 16 and 52 weeks.² The IMMpactful direct comparison now provides prospective data in a moderate psoriasis population that MAICs cannot fully capture.

The mechanistic distinction between the 2 agents is relevant to interpreting the magnitude of the difference. Risankizumab selectively blocks the p19 subunit of IL-23, interrupting upstream cytokine signaling that drives Th17-mediated skin inflammation. Deucravacitinib allosterically inhibits TYK2, a kinase involved in signaling downstream of IL-12, IL-23, and type I interferon receptors — a broader mechanism that does not achieve the same degree of IL-23 pathway selectivity. Whether the differential PASI 90 and PASI 100 rates at week 16 are sustained or narrow over longer follow-up will be a key question when 52-week IMMpactful data are presented later this year.¹

Magnolo N, Soung J, Sivamani RK, et al. Risankizumab vs deucravacitinib in adults with moderate plaque psoriasis: week 16 subgroup results from the IMMpactful study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster DV-017716.

Armstrong AW, Soliman AM, Gisondi P, et al. Matching-adjusted indirect comparison of risankizumab versus deucravacitinib in patients with moderate to severe plaque psoriasis. 

 2024;14(11):3071–3081. doi:10.1007/s13555-024-01293-y

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial

Podcasts

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

Swapnil Hiremath, MD, MPH, is a Staff Nephrologist at the Ottawa Hospital, a Professor in the Faculty of Medicine, cross appointed to the School of Epidemiology and Public Heath at the University of Ottawa, and also an Associate Scientist in the Clinical Epidemiology Programme at the Ottawa Hospital Research Institute.

Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.

Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH

CAR-T therapy shows potential for deep, durable remission in lupus nephritis, but questions remain on safety, durability, and patient selection.

Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

VESALIUS-CV: Evolocumab Cuts First MACE Risk in Diabetes Without Atherosclerosis

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension. 

Monthly Tonlamarsen Reduces Angiotensinogen, But No Significant Difference in Blood Pressure

Amy Sarma, MD, is the Cathy E. Minehan Endowed Chair in Cardiology and co-director of the Corrigan Women’s Heart Health Program and Cardiovascular Disease and Pregnancy Programs at the Massachusetts General Hospital.

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

Combatting Cardiovascular Risk in Postpartum and Menopausal Women, With Amy Sarma, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

Sustained Disease Reduction Observed at 1 Year of Icotrokinra in Psoriasis, With Linda Stein Gold, MD

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

KEEPsAKE-1: Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

Latest News

MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension

LV Unloading Before Delayed PCI Reduces Infarct Size by 1%, With Gregg Stone, MD, and Navin Kapur, MD

Roflumilast Cream 0.05% Well Tolerated in Children with Eczema, With Lawrence Eichenfield, MD

New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial